Slide 1: Q2 & H1/2024 Investors Call
August 2024 Q2 s& H1/2024 Investors Call
Slide 2: Forward-Looking Statement
FORWARD - LOOKING STATEMENT This presentation is not intended to provide investment or medical advice. It should be noted that some products under develo pme nt described herein have not been found safe or effective by any regulatory agency and are not approved for any use outside of clinical tr ial
Slide 3: Kamada - A Growing Global Commercial-Stage Biopharmaceutical Company
KEDRAB® CYTOGAM® HEPGAM B® VARIZIG® WINRHO® GLASSIA® KAMADA - A GROWING GLOBAL COMMERCIAL - STAGE BIOPHARMACEUTICAL COMPANY 6 FDA - Approved Products 16 % CAGR (from 2021) $ 158 - 162M 2024 Revenues Guidance $ 28 - 32M 2024 Adj. EBIDTA Guidance 4 Pillars of Growth LEADER IN SPECIALTY PLASMA THERAPIE
Slide 4: Delivering on Our Commitments
DELIVERING ON OUR COMMITMENTS 4
Slide 5: Kamada's Roadmap for Annual Double-Digit Growth
KAMADA ’ S ROADMAP FOR ANNUAL DOUBLE - DIGIT GROWTH 5 Organic Growth Portfolio of 6 FDA - approved products; Over 30 territories M&A Transactions Support growth through M&A transactions Plasma Collection Centers Each new collection center contributes annual revenues of $8M - $10M Inhaled AAT Phase I
Slide 6: Q2 - Continuing the Growth
Q 2 – 24 CONTINUING THE GROWTH REVENUE Q 2 - 24 $42.5 Q 2 - 23 $ 37.4 13% NET INCOME Q 2 - 24 $ 4.4 Q 2 - 23 $1.8 144 % GROSS PROFIT Q 2 - 24 $19.0 Q 2 - 23 $ 14.4 31 % Adj. EBITDA Q 2 - 24 $ 9.1 Q 2 - 23 $6.0 51 % DOUBLE DIGIT INCREASE 6 For reconciliation of Adjusted EBITDA please refer to slide 2
Slide 7: H1 2024 - Continuing the Growth
7 REVENUE H 1 - 24 $80.2 H 1 - 23 $ 68.2 18 % NET INCOME H 1 - 24 $ 6.8 H 1 - 23 $0.0 n/a GROSS PROFIT H 1 - 24 $35.7 H 1 - 23 $ 26.3 36 % Adj. EBITDA H 1 - 24 $ 16.6 H 1 - 23 $9.9 68 % DOUBLE DIGIT INCREASE H 1 – 24 CONTINUING THE GROWTH For reconciliation of Adjusted EBITDA please refer to slide 2
Slide 8: Annual Double-Digit Growth Trajectory
6 18 24 28 - 32 2021 2022 2023 2024 104 129 143 158 – 162 2021 2022 2023 2024 ADJUSTED EBITDA US$M 2024 represents annual guidance 2024 represents annual guidance ANNUAL DOUBLE - DIGIT GROWTH TRAJECTORY REVENUES US$M 16 % CAGR 77 % CAGR H 1 ĔČ Ţ đČƱ š H 1 čē Ţ đēƱ š 8
Slide 9: FDA-Approved Specialty Plasma Products
9 6 FDA - APPROVED SPECIALTY PLASMA PRODUCTS KEDRAB® [Rabies Immune Globulin (Human)] Post exposure prophylaxis of rabies infection CYTOGAM® [Cytomegalovirus Immune Globulin (Human)] Prophylaxis of CMV disease associated with transplants HEPGAM B® [Hepatitis B Immune Globulin (Human)] Prevention of
Slide 10: Distribution Segment Growth
DISTRIBUTION SEGMENT GROWTH More than 25 products exclusively licensed from leading international pharmaceutical companies, marketed in the Israeli market EXCLUSIVE DISTRIBUTOR IN ISRAEL FOR LEADING BIOPHARMACEUTICAL COMPANIES Key areas : plasma - derived, respiratory, rare diseases, infectious dise
Slide 11: M&A Transactions - Seeking the Next Breakthrough
11 Exploring strategic business development opportunities to identify potential acquisition or in - licensing Focusing on products synergistic to our existing commercial and/or production activities Strong financial position and proven successful M&A capabilities M&A TRANSACTIONS SEEKING THE NEXT BR
Slide 12: Kamada Plasma - Expanding Vertical Integration & Revenue Growth
12 Currently opening 2 additional centers: Houston, Texas ( H 2 - 24 ) San Antonio, Texas (H 1 - 25 ) Collecting hyper - immune plasma for our specialty IgG products and normal source plasma (NSP) to support revenue growth Average annual revenues of a mature collection center ranges from $ 8 M to $
Slide 13: Inhaled AAT Phase 3 Pivotal Study
INHALED AAT PHASE 3 PIVOTAL STUDY Non - Invasive, at - home treatment. Expected better ease of use and quality of life for AATD patients than current IV SOC Most effective mode of treatment for delivering therapeutic amounts of AAT directly into the airways Studied in more than 200 individuals to da
Slide 14: Inhaled AAT Phase 3 Pivotal Study - Market Opportunity
$ 2 Billion A substantial market opportunity ( 2028 ) Filed an IND amendment with revised statistical analysis plan and study protocol, expecting FDA feedback during H 2 / 2024 FDA recently reconfirmed overall study design, endorsed positive safety data to date, and expressed willingness to potentia
Slide 15: Financial Summary
15 US $ M H1/24 H1/23 Q2/24 Q2/23 FY 2023 DETAILS PROPRIETARY 72.9 55.0 39.1 30.9 115.5 Driven by two key growth drivers, KEDRAB® & CYTOGAM® DISTRIBUTION 7.3 13.2 3.3 6.5 27.1 TOTAL REVENUES 80.2 68.2 42.5 37.4 142.5 18% YoY increase; H1 revenues - 50% of mid - point annual guidance GROSS PROFIT 35.
Slide 16: Non-IFRS Measures - Adjusted EBITDA
16 NON - IFRS MEASURES – ADJUSTED EBITDA US $ M H 1 / 24 H1/23 Q 2 / 24 Q2/23 2023 NET PROFIT 6.8 0.0 4.4 1.8 8.3 TAXES ON INCOME 0.1 0.1 0.1 0.1 0.1 REVALUATION OF ACQUISITION RELATED CONTINGENT CONSIDERATION 3.6 2.1 1.7 0.3 1.0 OTHER FINANCIAL EXPENSE, NET ( 0.8 ) 0.7 ( 0.6 ) 0.4 0.7 AMORTIZATION
Slide 17: Kamada - Significant Upside Potential
KEDRAB® CYTOGAM® HEPGAM B® VARIZIG® WINRHO® GLASSIA® KAMADA – SIGNIFICANT UPSIDE POTENTIAL 6 FDA - Approved Products 16 % CAGR (from 2021 ) $ 158 - 162 M 2024 Revenues Guidance $28 - 32M 2024 Adj. EBIDTA Guidance 4 Pillars of Growth $ 56.6 M Cash (Q 2 / 2024 ) DELIVERING ON OUR COMMITMENTS 17 Organi
Slide 18: Thank You
THANK YOU www.kamada.com